AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Atai Life Sciences CEO discusses Phase 2b trial results for BPL-003 and outlines next steps for treatment-resistant depression.
ByAinvest
Wednesday, Jul 30, 2025 1:53 pm ET1min read
atai Life Sciences CEO Dr. Srinivas Rao discussed the company's Phase 2b trial results for BPL-003, a short-acting psychedelic for treatment-resistant depression. The study showed strong efficacy and durability, comparable to psilocybin but with a shorter duration of effect. Rao also previewed next steps, including data from an open-label extension and a two-dose induction strategy, and confirmed plans to meet with regulators for end-of-Phase 2 guidance.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet